Effect of Risperidone on BDNF-TrkB Signaling Pathway in Rat Brain

YU Bo, WANG Xue, WEI Jin-xue. et al

Abstract

To investigate the effect of risperidone on the expression of brain-derived neurotrophic factor (BDNF) and its receptors» tyrosine kinase receptor (TrkB) and P75 neurotrophin receptor (P75NTR) in rat brain. Methods Sixteen SI) rats were divided into two groups (;/ = 8 for each group). The rats in experimental group were treated with risperidone CO. 25 mg/(kg • d)J for 14 d, while the control group was given placebo. Total RNA sample in prefrontal cortex, temporal cortex and hippocampus was extracted, and the expression of BDNF, TrkB and P75NTR mRNA were determined by quantitative real-time PCR. Results The treatment of risperidone significantly up-regulated the expressions of BDNF and TrkB in prefrontal cortex, temporal cortex and hippocampus, while the expression of P75NTR was not significantly changed. Conclusion Risperidone upregulated BDNF-TrkB signaling, but not BDNF-P75NTR signaling, which may be helpful for the further pharmacological study of risperidone.


Keywords: Risperidone, BDNF, TrkB P75NTR

 

Full Text:

PDF


References


Goldner EM, Hsu L, Waraich P, et al. Prevalence and incidence studies of schizophrenic disorders; a systematic review of the literature. Can J Psychiatry, 2002; 47 ( 9 ): 833- 843.

Wright IC, Rabe-Hesketh S, Woodruff PW. et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry,2000; 157( 1): 16-25.

Wright IC, Ellison ZR, Sharma T, et al. Mapping of grey matter changes in schizophrenia. Schizophr Res, 1999; 35 (1): 1-14.

Chiapponi C, Piras F, Piras F, et al. Cortical grey matter and subcortical white matter brain microstructural changes in schizophrenia are localised and age independent; a case-control diffusion tensor imaging study. PLoS One, 2013; 8 (10): e75115. doi; 10. 1371/journal, pone. 0075115.

Rajkowska G. Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex; a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry, 1998;55(3);215-224.

Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry,1997;54(10) :943-952.

Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry,2000;57(1);65-73.

Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography. Neuroscience, 1995;69(2): 339-343.

Jarskog LF. Apoptosis in schizophrenia; pathophysiologic and therapeutic considerations. Curr Opin Psychiatry,2006 ; 19(3): 307-312.

Voineskos D, Rogasch NC, Rajji TK. et al. A review of evidence linking disrupted neural plasticity to schizophrenia. Can J Psychiatry,2013;58(2):86-92.

Thome J, Foley P, Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. Review article. J Neural Transm,1998; 105С1) ;85-100.

Altar С A, Distefano PS. Neurotrophin trafficking by anterograde transport. Trends Neurosci, 1998; 21 ( 10): 433- 437.

Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol,2014;220:223-250. doi; 10. 1007/978-3-642-45106-5_9.

Fujii T, Kunugi H. p75NTR as a therapeutic target for neuropsychiatric diseases. Curr Mol Pharmacol,2009 ;2( 1); 70- 76.

Pillai A, Kale A, Joshi S,et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects; correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol.2010; 13(4);535-539.

Issa G, Wilson C, Terry AV, et al. An inverse relationship between cortisol and BDNF levels in schizophrenia; data from human postmortem and animal studies. Neurobiol Dis»2010;39 (3):327-333.

Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals,2008; 16(2-3): 183-193.

Durany N, Michel T, Zochling R, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res,2001 ;52( 1-2) ;79-86.

Lee AH. Lange С , Ricken R, et al. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol,2011;31(3);334-336.

Desamericq G, Schurhoff F. Meary A, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol,2011;70(2): 127- 134.

Nandra KS, Agius M. The differences between typical and atypical antipsychotics; the effects on neurogenesis. Psychiatr Danub,2012;24 (Suppl 1):S95-S99.

Ajami A, Hosseini SH. Taghipour M et al. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment. Scand J Immunol .2014 ; 80(1): 36-42.

Zhang XR. Wang YX, Zhang ZJ. et al. The effect of chronic antipsychotic drug on hypothalamic expression of neural nitric oxide synthase and dopamine 1)2 receptor in the male rat. PLoS One,2012;7(4) ;e33247. doi:10. 1371/journal, pone. 0033247. Lu B, Martinowich K. Cell biology of BDNF and its reles'ance to schizophrenia. Novartis Found Symp. 2008; 289; 119-129; discussion 129-135, 193-115.

Yang J. Harte-Hargrove LC, Siao CJ, et al. proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus. Cell Rep,2014;7(3);796-806.

Xia Y, Wang CZ, Liu J. et al. Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways. Neuropharmacology .2010; 58(2): 330-336.

Bredy TW, Wu H, Crego C, et al. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem, 2007;14(4) ;268-276.


Refbacks

  • There are currently no refbacks.